TriMod Therapeutics Ltd
Combining two medicines - a TLR agonist and a Kinase Inhibitor - mobilises the powerful immune system to target and eradicate cancers.
TriMod is a seed-capital funded Biotechnology company. Founded on ground-breaking and patented science, we are developing a combination therapy that enables the immune system to seek out and destroy existing tumours. Efficacy has been seen in pre-clinical in vivo models of Melanoma, Colon and Lung cancers. Using our seed capital we have identified optimal human-ready molecules. Using Series A financing of €7.5 will be testing in patients in 2014.